Longboard Pharmaceuticals Inc
LBPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.34B
Close$
$0.61
99% downside
Current Fair Value
99% downsideOvervalued by 99% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.34 Billion |
|---|---|
| Enterprise Value | $2.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.39 |
| Beta | 1.09 |
| Outstanding Shares | 38,957,524 |
Return
| Return on Equity | -27.74% |
|---|---|
| Return on Assets | -25.70% |
| Return on Invested Capital | -31.38% |
Valuation & Multiples
| P/E Ratio | -25.05 |
|---|---|
| PEG | -27.91 |
| Price to Sales | - |
| Price to Book Ratio | 8.57 |
| Enterprise Value to Revenue | 289293.86 |
| Enterprise Value to EBIT | -26.46 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Longboard Pharmaceuticals Inc
6 employeesLongboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena to advance a portfolio of centra...